ArticleCureus2024
Investigation of the Relationship Between Brown HT Dye Exposure and Mammary Tumor Development in Female Rats: An Assessment of the Potential Risk of Breast Cancer.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAzo dyes featuring one (monoazo) or several intramolecular NQN bonds are utilized in the food, pharmaceutical, and textile industries. The food azo dye chocolate brown HT (E155) adversely affects hepatic and renal function upon prolonged consumption. This study aimed to assess the carcinogenic potential of E155 in the development of mammary tumors and breast cancer.
methodsA total of 20 female Long-Evans rats (eight to nine weeks old) were randomly assigned to five groups, each consisting of four rats. The control (female control) group received a regular diet, whereas the positive control (female positive control) group received 7,12-dimethylbenz(a)anthracene. The remaining three groups received 200, 400, or 600 mg/kg body weight (BW)/day E155 for 40 weeks. Tumor development, BW, and biochemical, hematological, and histological data were monitored.
resultsBW decreased significantly with increasing dosages in the female moderate dose (FMD) group. Blood counts indicated potential microcytic anemia and inflammation in the treatment groups, especially in the female high-dose (FHD) group. E155 dose-dependently impaired renal function and increased blood creatinine and uric acid levels. Elevated serum glutamic pyruvic transaminase (SGPT) and serum glutamic-oxaloacetic transaminase levels indicate abnormal liver function. FHD animals had more tumors and larger sizes. Higher alpha-fetoprotein (AFP) and cancer antigen levels were detected even at low doses. Histopathological analysis revealed that E155 causes mammary gland fibroadenomas, ductal carcinoma in situ, and hyperplasia. It also causes circular layer granulomas, fibrosis, and crypt abscesses in the intestines of FMD and FHD.
conclusionThe current study suggests that prolonged exposure to E155 may result in a higher incidence of mammary tumors, indicating an elevated risk for the onset of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.